Safety profiles of leading nonsteroidal anti-inflammatory drugs

American Journal of Medicine

Volumn 105, Issue 5 A, 1998, Pages 39S-43S

  Rothstein, Richard ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; IBUPROFEN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; PLACEBO; PRODRUG;

CONFERENCE PAPER; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; ENTERIC COATED TABLET; ENTEROHEPATIC CIRCULATION; GASTROINTESTINAL TOXICITY; HUMAN; PRIORITY JOURNAL;

EID: 0032476569     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00280-0     Document Type: Conference Paper

References (47)

1. Taha A.S., Dahill S., Sturrock R.D., et al. Predicting NSAID related ulcers assessment of clinical and pathological risk factors and importance of differences in NSAID. Gut. 35:1994;891-895.
2. Henry D., Lim L.L.-Y., García Rodríguez L.A., et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs results of a collaborative meta-analysis . BMJ. 312:1996;1563-1566.
3. Fries J.F., Williams C.A., Bloch D.A. The relative toxicity of nonsteroidal antiinflammatory drugs. Arthritis Rheum. 34:1991;1353-1360.
4. Singh G., Terry R., Ramey D.R., et al. Comparative GI toxicity of NSAIDs. (Abstr.) Arthritis Rheum. 40:(suppl):1997;S115.
5. García Rodríguez L.A., Cattaruzzi C., Troncon M.G., Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med. 158:1998;33-39.
6. Vane J. Towards a better aspirin. Nature. 367:1994;215-216.
7. Schoen R.T., Vender R.J. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med. 86:1989;449-458.
8. Reuter B.K., Davies N.M., Wallace J.L. Nonsteroidal anti-inflammatory drug enteropathy in rats role of permeability, bacteria, and enterohepatic circulation . Gastroenterology. 112:1997;109-117.
9. Henry D., Page J., Whyte I., et al. Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects results of a case-control study . Br J Clin Pharmacol. 44:1997;85-90.
10. Henry D., Dobson A., Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology. 105:1993;1078-1088.
11. Schafer A.I. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol. 35:1995;209-219.
12. Kaufman D.W., Kelly J.P., Sheehan J.E., et al. Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding. Clin Pharmacol Ther. 53:1993;485-494.
13. Janssen F.W., Jusko W.J., Chiang S.T., et al. Metabolism and kinetics of oxaprozin in normal subjects. Clin Pharmacol Ther. 27:1980;352-362.
14. Lewis A.J., Carlson R.P., Chang J., et al. The pharmacological profile of oxaprozin, an antiinflammatory and analgesic agent with low gastrointestinal toxicity. Curr Ther Res. 34:1983;777-794.
15. Poiley J.E., Spindler J.S., Clarke J.P., Brame C.L. Nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis a comparison of oxaprozin and ibuprofen . Semin Arthritis Rheum. 15:(suppl 2):1986;59-65.
16. Appelrouth D.J., Chodock A.L., Miller J.L., Powell W.R. A comparison of single daily doses of oxaprozin with multiple daily doses of ibuprofen for the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 15:(suppl 2):1986;54-58.
17. Barber J.V., Collins R.L., Kitridou R.C., et al. The efficacy and safety of single daily doses of oxaprozin in the treatment of rheumatoid arthritis a comparison with aspirin . Semin Arthritis Rheum. 15:(suppl 2):1986;47-53.
18. Kolodny A.L., Klipper A.R., Harris B.K., et al. The efficacy and safety of single daily doses of oxaprozin in the treatment of osteoarthritis a comparison with aspirin . Semin Arthritis Rheum. 15:(suppl 2):1986;72-79.
19. Powell W.R., Miller J.L., Sheldon W.B. Once-daily oxaprozin and piroxicam compared in osteoarthritis. Semin Arthritis Rheum. 15:(suppl 2):1986;80-85.
20. Dahl S.L., Ward J.R. Efficacy and tolerability of oxaprozin in the elderly. Semin Arthritis Rheum. 15:(suppl 2):1986;40-46.
21. Singh G, Terry R, Ramey DR, et al. Comparative GI toxicity of NSAIDs. (Abstr.) Paper presented at: XIX ILAR Congress of Rheumatology; June 8-13, 1997; Singapore.
22. Makarowski W., Weaver A., Rubin B., et al. The efficacy, tolerability, and safety of 1200 mg/d of oxaprozin and 1500 mg/d of nabumetone in the treatment of patients with osteoarthritis of the knee. Clin Ther. 18:1996;114-124.
23. Weaver A., Rubin B., Caldwell J., et al. Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee. Clin Ther. 17:1995;735-745.
24. Meade E.A., Smith W.L., DeWitt D.L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 268:1993;6610-6614.
25. Churchill L., Graham A.G., Shih C.-K., et al. Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Inflammopharmacology. 4:1996;125-135.
26. 2 production. Inflamm Res. 45:1996;246-253.
27. Riendeau D., Percival M.D., Boyce S., et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 121:1997;105-117.
28. 51Cr). J Clin Pharmacol. 29:1989;225-229.
29. Lussier A., LeBel E. Radiochromium (chromium-51) evaluation of gastrointestinal blood loss associated with placebo, aspirin, and nabumetone. Am J Med. 83:1987;15-18.
30. Roth S.H., Tindall E.A., Jain A.K., et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med. 153:1993;2565-2571.
31. Roth S.H. Upper gastrointestinal safety with nabumetone. J Rheumatol. 19:(suppl 36):1992;74-79.
32. Roth S.H., Bennett R., Caldron P., et al. A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen. J Rheumatol. 21:1994;1118-1123.
33. Lipani J.A., Poland M. Clinical update of the relative safety of nabumetone in long-term clinical trials. Inflammopharmacology. 3:1995;351-361.
34. Glaser K., Sung M.-L., O Neill K., et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol. 281:1995;107-111.
35. Kawai S, Nishida S, Kato M, et al. Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human synovial cells and platelets. (Abstr.) Paper presented at: XIX ILAR Congress of Rheumatology; June 8-13, 1997; Singapore.
36. Laneuville O., Breuer D.K., Dewitt D.L., et al. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 271:1994;927-934.
37. Adams L., Neuman R.G., Sachs J., Bralow S.P. Efficacy and gastric safety of etodolac as determined in cultured human gastric and synovial cells. (Abstr.) Gastroenterology. 98:(suppl):1990;A14.
38. Brocks D.R., Jamali F. Etodolac clinical pharmacokinetics. Clin Pharmacokinet. 26:1994;259-274.
39. Russell R.I. Endoscopic evaluation of etodolac and naproxen, and their relative effects on gastric and duodenal prostaglandins. Rheumatol Int. 10:(suppl):1990;17-21.
40. Taha A.S., McLaughlin S., Sturrock R.D., Russell R.I. Evaluation of the efficacy and comparative effects on gastric and duodenal mucosa of etodolac and naproxen in patients with rheumatoid arthritis using endoscopy. Br J Rheumatol. 28:1989;329-332.
41. Lanza F., Rack M.F., Lynn M., et al. An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa. J Rheumatol. 14:1987;338-341.
42. Bianchi Porro G., Caruso I., Petrillo M., et al. A double-blind gastroscopic evaluation of the effects of etodolac and naproxen on the gastrointestinal mucosa of rheumatic patients. J Intern Med. 229:1991;5-8.
43. Perpignano G., Bogliolo A., Puccetti L. Double-blind comparison of the efficacy and safety of etodolac SR 600 mg u.i.d. and of tenoxicam 20 mg u.i.d. in elderly patients with osteoarthritis of the hip and of the knee. Int J Clin Pharmacol Res. 14:1994;203-216.
44. Laine L., Sloane R., Ferretti M., Cominelli F. A randomized, double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc. 42:1995;428-433.
45. Lipscomb G.R., Wallis N., Armstrong G., et al. Gastric mucosal adaptation to etodolac and naproxen. Aliment Pharmacol Ther. 9:1995;379-385.
46. Taha A.S., Angerson W., Nakshabendi I., et al. Gastric and duodenal mucosal blood flow in patients receiving non-steroidal anti-inflammatory drugs influence of age, smoking, ulceration and Helicobacter pylori. Aliment Pharmacol Ther. 7:1993;41-45.
47. Etodolac safer than other NSAIDs? Scrip. 1616:1991;28.